ibrutinib,rituximab
abbvie,janssen
[' ibru', 'ritux', 'lymsm']
dr. martin dreyling presents results of the triangle rct in pts w/ newly dx mcl investigating rchop/rdhap (chemo) -&gt; asct -&gt; obs vs chemo+ ibrutinib -&gt; asct -&gt; ibr mant x2y vs chemo &gt; ibr maint x2y, +/- ritux in all groups. 870 pts randomized. #lymsm #ash22 1/2 
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????